Advertisement

Topics

Pharmacokinetic Studies Participation Survey

2014-08-27 03:21:24 | BioPortfolio

Summary

Background:

- A pharmacokinetic (PK) study of a new drug involves taking several blood samples over a period of time from study participants to determine how the body handles the substance. These studies provide critical information about new drugs.

- Often, patients or parents of children in drug studies choose not to participate in optional PK studies that are part of the study protocol.

- A better understanding of why patients or families do or do not agree to participate in PK studies may help researchers make it easier for people to participate in them.

Objectives:

- To learn why some people do or do not agree to participate in PK blood sampling studies.

Eligibility:

- Patients 18 years of age and older and parents or guardians of children who are participating in a study of a drug that includes the option of participating in PK sampling.

Design:

- Participants fill out a 2-page survey asking about why they did or did not participate in the study's PK sampling.

Description

Background:

Pharmacokinetic studies provide critical information about the disposition of anticancer drugs in children. However, participation of children in the pharmacokinetic portion of phase I studies is optional when there is not prospect of direct benefit to the child.

The rate of participation in optional PK studies on COG Phase I Consortium Studies has been 60-70%.

There are no recent data on why families do or do not agree to participate in optional PK studies. Understanding families' reasons may reveal barriers to participation that could be overcome, leading to increased participation rates in optional PK sampling.

Objectives:

To use a simple 2 page survey to gather preliminary information on why parents/children agree to participate in Phase I Studies do or do not agree to participate in the voluntary pharmacokinetic (PK) portion of those studies.

Eligibility:

Subjects (greater than or equal to 18 years old) or parents/guardians of subjects who are minors who consented to Phase I studies with optional PK sampling with the previous 4 weeks.

Consent for the primary Phase I treatment protocol must be active (not withdrawn).

No limit on the number of prior Phase I studies in which the subject or subject's child participated.

Subjects may only participate in this study once.

Design:

The individual who provided consent to the treatment study that included optional PK sampling will complete a short questionnaire.

Subjects (n=50) from a convenience sample will complete and return the questionnaire.

Reasons for participating or agreeing to participate will be tabulated. Correlations between answers and subject demographics, time required by PK, need for additional IV will be sought.

Subjects will meet off study criteria when the questionnaire is returned, lost to follow up, or consent for data submission to this or the primary treatment protocol is withdrawn.

The total accrual is 50 subjects. Accrual ceiling at the POB, NCI is 25 subjects.

Study Design

Time Perspective: Prospective

Conditions

Relapsed Solid Tumors

Location

National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda
Maryland
United States
20892

Status

Completed

Source

National Institutes of Health Clinical Center (CC)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:21:24-0400

Clinical Trials [2409 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

Phase 1, open-labeled, dose escalation safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.

CBT-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

The purpose of this study is to determine the safety, tolerability, and recommended dose of CBT-501 in individuals with advanced or relapsed or recurrent solid tumors.

A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors

Phase 1, open-labeled, safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.

Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors

This is a 4-part, open-label, Phase 1/1b, dose escalation study in pediatric patients with relapsed refractory solid tumors; 2) primary CNS tumors; 3) neuroblastoma; and 4) non-neuroblasto...

Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Including Central Nervous System Tumors

This study is a Phase I study using vinblastine and sirolimus in patients with relapsed solid tumors including selected brain tumors and lymphoma. The investigators hypothesis is that the ...

PubMed Articles [6303 Associated PubMed Articles listed on BioPortfolio]

Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.

Sonidegib (LDE225) is a potent, selective Hedgehog (Hh) inhibitor of SMOOTHENED. This study explored the safety and pharmacokinetics (PK) of sonidegib in children with relapsed/recurrent tumors follow...

A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

The c-Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c-Met receptor tyrosine kinase. A phase 1 and pharmacokinetic (PK) ...

Prognostic Significance of Dementia in Older Adults with Solid Tumors.

The public health burden of cancer and dementia in the geriatric population is well documented. There is limited data on how dementia predicts mortality among geriatric patients with solid tumors. The...

Pediatric solid tumors in Africa: different biology?

To review the recent literature regarding biologic characteristics of pediatric solid tumors in African children.

Varlilumab Is Safe and Active in Patients with Advanced Solid Tumors.

Varlilumab activates the CD27 pathway in T cells to promote antitumor activity in solid tumors.

Medical and Biotech [MESH] Definitions

An alkylating agent of value against both hematologic malignancies and solid tumors.

An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.

A smooth, solid or cystic fibroepithelial (FIBROEPITHELIAL NEOPLASMS) tumor, usually found in the OVARIES but can also be found in the adnexal region and the KIDNEYS. It consists of a fibrous stroma with nests of epithelial cells that sometimes resemble the transitional cells lining the urinary bladder. Brenner tumors generally are benign and asymptomatic. Malignant Brenner tumors have been reported.

A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.

A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.

More From BioPortfolio on "Pharmacokinetic Studies Participation Survey"

Quick Search
Advertisement
 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Searches Linking to this Trial